The lowering of the price target by a major financial institution like Morgan Stanley could potentially lead to a decrease in Pfizer's stock price in the short term. The Equal-Weight rating suggests that the stock is expected to perform in line with the market, but the lowered price target may cause some investors to reassess their positions.